Agents useful for the treatment of various metabolic disorders, such as insulinresistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia,fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosisare disclosed, wherein n is 1 or 2； m is 0, 1, 2, 3 or 4； q is 0 or 1； t is 0 or 1； Ris alkyl having from 1 to3 carbon atoms； R is hydrogen, halo, alkylhaving from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms； A is phenyl,unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkylhaving 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms,and perfluoromethoxy； or cycloalkyl having from 3 to 6 ring carbon atoms whereinthe cycloalkyl is unsubstituted or one or two ring carbons are independentlymono-substituted by methyl or ethyl； or a 5 or 6 membered heteroaromatic ringhaving 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ringis covalently bound to the remainder of the compound of formula (I) by a ring carbon.Alternatively, the agent can be a pharmaceutically acceptable salt of the compoundof formula (I).
